Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Provided By GlobeNewswire
Last update: Oct 9, 2025
Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025
Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 degrader in collaboration with Gilead, showing potent pathway inhibition and efficacy in a dermatitis model
Read more at globenewswire.comNASDAQ:NRIX (12/10/2025, 1:22:33 PM)
19.13
-0.42 (-2.15%)
Find more stocks in the Stock Screener
